HEADER MEMBRANE PROTEIN 11-MAR-12 4AMI TITLE TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND BOUND TITLE 2 BIASED AGONIST BUCINDOLOL COMPND MOL_ID: 1; COMPND 2 MOLECULE: BETA-1 ADRENERGIC RECEPTOR; COMPND 3 CHAIN: A, B; COMPND 4 FRAGMENT: RESIDUES 33-243,272-368; COMPND 5 SYNONYM: BETA-1 ADRENORECEPTOR, BETA-1 ADRENOCEPTOR, BETA-T; COMPND 6 ENGINEERED: YES; COMPND 7 MUTATION: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: MELEAGRIS GALLOPAVO; SOURCE 3 ORGANISM_COMMON: TURKEY; SOURCE 4 ORGANISM_TAXID: 9103; SOURCE 5 CELL: ERYTHROCYTE; SOURCE 6 EXPRESSION_SYSTEM: TRICHOPLUSIA NI; SOURCE 7 EXPRESSION_SYSTEM_COMMON: CABBAGE LOOPER; SOURCE 8 EXPRESSION_SYSTEM_TAXID: 7111; SOURCE 9 EXPRESSION_SYSTEM_CELL_LINE: HIGH FIVE; SOURCE 10 EXPRESSION_SYSTEM_VECTOR_TYPE: BACULOVIRUS; SOURCE 11 EXPRESSION_SYSTEM_PLASMID: PBACPAK8 KEYWDS MEMBRANE PROTEIN, 7TMR BETA1-ADRENOCEPTOR, STABILISING MUTATIONS, KEYWDS 2 BIASED AGONIST EXPDTA X-RAY DIFFRACTION AUTHOR T.WARNE,P.C.EDWARDS,A.G.LESLIE,C.G.TATE REVDAT 6 13-NOV-24 4AMI 1 REMARK REVDAT 5 20-DEC-23 4AMI 1 REMARK REVDAT 4 03-APR-19 4AMI 1 SOURCE REMARK REVDAT 3 03-DEC-14 4AMI 1 REMARK REVDAT 2 30-MAY-12 4AMI 1 COMPND JRNL REMARK DBREF REVDAT 1 23-MAY-12 4AMI 0 JRNL AUTH T.WARNE,P.C.EDWARDS,A.G.LESLIE,C.G.TATE JRNL TITL CRYSTAL STRUCTURES OF A STABILIZED BETA1-ADRENOCEPTOR BOUND JRNL TITL 2 TO THE BIASED AGONISTS BUCINDOLOL AND CARVEDILOL JRNL REF STRUCTURE V. 20 841 2012 JRNL REFN ISSN 0969-2126 JRNL PMID 22579251 JRNL DOI 10.1016/J.STR.2012.03.014 REMARK 2 REMARK 2 RESOLUTION. 3.20 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : REFMAC 5.7.0019 REMARK 3 AUTHORS : MURSHUDOV,SKUBAK,LEBEDEV,PANNU,STEINER, REMARK 3 : NICHOLLS,WINN,LONG,VAGIN REMARK 3 REMARK 3 REFINEMENT TARGET : MAXIMUM LIKELIHOOD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 3.20 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 44.82 REMARK 3 DATA CUTOFF (SIGMA(F)) : NULL REMARK 3 COMPLETENESS FOR RANGE (%) : 95.7 REMARK 3 NUMBER OF REFLECTIONS : 16557 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.244 REMARK 3 R VALUE (WORKING SET) : 0.242 REMARK 3 FREE R VALUE : 0.279 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.100 REMARK 3 FREE R VALUE TEST SET COUNT : 898 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 20 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 3.20 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 3.28 REMARK 3 REFLECTION IN BIN (WORKING SET) : 1091 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 86.69 REMARK 3 BIN R VALUE (WORKING SET) : 0.3500 REMARK 3 BIN FREE R VALUE SET COUNT : 55 REMARK 3 BIN FREE R VALUE : 0.3840 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 4529 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 131 REMARK 3 SOLVENT ATOMS : 13 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 92.66 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -0.17000 REMARK 3 B22 (A**2) : 3.34000 REMARK 3 B33 (A**2) : -2.55000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.88000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR. REMARK 3 ESU BASED ON R VALUE (A): NULL REMARK 3 ESU BASED ON FREE R VALUE (A): 0.490 REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): 0.348 REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): 19.890 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.910 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.844 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES COUNT RMS WEIGHT REMARK 3 BOND LENGTHS REFINED ATOMS (A): 4771 ; 0.005 ; 0.020 REMARK 3 BOND LENGTHS OTHERS (A): NULL ; NULL ; NULL REMARK 3 BOND ANGLES REFINED ATOMS (DEGREES): 6486 ; 0.984 ; 1.977 REMARK 3 BOND ANGLES OTHERS (DEGREES): NULL ; NULL ; NULL REMARK 3 TORSION ANGLES, PERIOD 1 (DEGREES): 566 ; 4.238 ; 5.000 REMARK 3 TORSION ANGLES, PERIOD 2 (DEGREES): 174 ;34.455 ;22.184 REMARK 3 TORSION ANGLES, PERIOD 3 (DEGREES): 781 ;14.575 ;15.000 REMARK 3 TORSION ANGLES, PERIOD 4 (DEGREES): 32 ;13.600 ;15.000 REMARK 3 CHIRAL-CENTER RESTRAINTS (A**3): 767 ; 0.067 ; 0.200 REMARK 3 GENERAL PLANES REFINED ATOMS (A): 3419 ; 0.003 ; 0.021 REMARK 3 GENERAL PLANES OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED CONTACTS REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED CONTACTS OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION OTHERS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) OTHERS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 MAIN-CHAIN BOND REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 MAIN-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN BOND REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 ANISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 RIGID-BOND RESTRAINTS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; FREE ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; BONDED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 NCS RESTRAINTS STATISTICS REMARK 3 NUMBER OF DIFFERENT NCS GROUPS : 1 REMARK 3 REMARK 3 NCS GROUP NUMBER : 1 REMARK 3 CHAIN NAMES : B A REMARK 3 NUMBER OF COMPONENTS NCS GROUP : 7 REMARK 3 COMPONENT C SSSEQI TO C SSSEQI CODE REMARK 3 1 B 47 B 103 1 REMARK 3 1 A 47 A 103 1 REMARK 3 2 B 113 B 140 1 REMARK 3 2 A 113 A 140 1 REMARK 3 3 B 153 B 170 1 REMARK 3 3 A 153 A 170 1 REMARK 3 4 B 176 B 182 1 REMARK 3 4 A 176 A 182 1 REMARK 3 5 B 202 B 230 1 REMARK 3 5 A 202 A 230 1 REMARK 3 6 B 291 B 311 1 REMARK 3 6 A 291 A 311 1 REMARK 3 7 B 329 B 358 1 REMARK 3 7 A 329 A 358 1 REMARK 3 GROUP CHAIN COUNT RMS WEIGHT REMARK 3 TIGHT THERMAL 1 A (A**2): 1469 ; 4.80 ; 0.50 REMARK 3 TIGHT THERMAL 1 B (A**2): 1469 ; 4.80 ; 0.50 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : MASK REMARK 3 PARAMETERS FOR MASK CALCULATION REMARK 3 VDW PROBE RADIUS : 1.20 REMARK 3 ION PROBE RADIUS : 0.80 REMARK 3 SHRINKAGE RADIUS : 0.80 REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: HYDROGENS HAVE BEEN ADDED IN THE RIDING REMARK 3 POSITIONS. HYDROGENS HAVE BEEN USED IF PRESENT IN THE INPUT. U REMARK 3 VALUES REFINED INDIVIDUALLY. REMARK 4 REMARK 4 4AMI COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 11-MAR-12. REMARK 100 THE DEPOSITION ID IS D_1290051639. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 03-JUN-12 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 9.0 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : ESRF REMARK 200 BEAMLINE : ID23-2 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.8726 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : MARMOSAIC 225 MM CCD REMARK 200 INTENSITY-INTEGRATION SOFTWARE : MOSFLM REMARK 200 DATA SCALING SOFTWARE : SCALA REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 17466 REMARK 200 RESOLUTION RANGE HIGH (A) : 3.200 REMARK 200 RESOLUTION RANGE LOW (A) : 52.100 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 2.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 95.9 REMARK 200 DATA REDUNDANCY : 5.300 REMARK 200 R MERGE (I) : 0.10000 REMARK 200 R SYM (I) : NULL REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 9.9000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 3.20 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 3.37 REMARK 200 COMPLETENESS FOR SHELL (%) : 86.5 REMARK 200 DATA REDUNDANCY IN SHELL : 5.40 REMARK 200 R MERGE FOR SHELL (I) : 0.60000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 <I/SIGMA(I)> FOR SHELL : 2.500 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHASER REMARK 200 STARTING MODEL: PDB ENTRY 2Y02 REMARK 200 REMARK 200 REMARK: NONE REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 67.80 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 3.82 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 0.1 M BICINE PH 9.0, 22% PEG 600, 4 REMARK 280 DEGREES CELSIUS., TEMPERATURE 277K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 21 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 30.33850 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 400 REMARK 400 COMPOUND REMARK 400 ENGINEERED RESIDUE IN CHAIN A, ARG 68 TO SER REMARK 400 ENGINEERED RESIDUE IN CHAIN A, MET 90 TO VAL REMARK 400 ENGINEERED RESIDUE IN CHAIN A, CYS 116 TO LEU REMARK 400 ENGINEERED RESIDUE IN CHAIN A, TYR 227 TO ALA REMARK 400 ENGINEERED RESIDUE IN CHAIN A, ALA 282 TO LEU REMARK 400 ENGINEERED RESIDUE IN CHAIN A, PHE 327 TO ALA REMARK 400 ENGINEERED RESIDUE IN CHAIN A, PHE 338 TO MET REMARK 400 ENGINEERED RESIDUE IN CHAIN A, CYS 358 TO ALA REMARK 400 ENGINEERED RESIDUE IN CHAIN B, ARG 68 TO SER REMARK 400 ENGINEERED RESIDUE IN CHAIN B, MET 90 TO VAL REMARK 400 ENGINEERED RESIDUE IN CHAIN B, CYS 116 TO LEU REMARK 400 ENGINEERED RESIDUE IN CHAIN B, TYR 227 TO ALA REMARK 400 ENGINEERED RESIDUE IN CHAIN B, ALA 282 TO LEU REMARK 400 ENGINEERED RESIDUE IN CHAIN B, PHE 327 TO ALA REMARK 400 ENGINEERED RESIDUE IN CHAIN B, PHE 338 TO MET REMARK 400 ENGINEERED RESIDUE IN CHAIN B, CYS 358 TO ALA REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 MET A 31 REMARK 465 GLY A 32 REMARK 465 ILE A 238 REMARK 465 ARG A 239 REMARK 465 LYS A 240 REMARK 465 ILE A 241 REMARK 465 ASP A 242 REMARK 465 ARG A 243 REMARK 465 ALA A 272 REMARK 465 SER A 273 REMARK 465 LYS A 274 REMARK 465 ARG A 275 REMARK 465 LYS A 276 REMARK 465 THR A 277 REMARK 465 SER A 278 REMARK 465 ARG A 279 REMARK 465 VAL A 280 REMARK 465 MET A 281 REMARK 465 PHE A 359 REMARK 465 PRO A 360 REMARK 465 ARG A 361 REMARK 465 LYS A 362 REMARK 465 ALA A 363 REMARK 465 ASP A 364 REMARK 465 ARG A 365 REMARK 465 ARG A 366 REMARK 465 LEU A 367 REMARK 465 HIS A 368 REMARK 465 HIS A 369 REMARK 465 HIS A 370 REMARK 465 HIS A 371 REMARK 465 HIS A 372 REMARK 465 HIS A 373 REMARK 465 MET B 31 REMARK 465 GLY B 32 REMARK 465 ILE B 241 REMARK 465 ASP B 242 REMARK 465 ARG B 243 REMARK 465 ALA B 272 REMARK 465 SER B 273 REMARK 465 LYS B 274 REMARK 465 ARG B 275 REMARK 465 LYS B 276 REMARK 465 THR B 277 REMARK 465 ALA B 358 REMARK 465 PHE B 359 REMARK 465 PRO B 360 REMARK 465 ARG B 361 REMARK 465 LYS B 362 REMARK 465 ALA B 363 REMARK 465 ASP B 364 REMARK 465 ARG B 365 REMARK 465 ARG B 366 REMARK 465 LEU B 367 REMARK 465 HIS B 368 REMARK 465 HIS B 369 REMARK 465 HIS B 370 REMARK 465 HIS B 371 REMARK 465 HIS B 372 REMARK 465 HIS B 373 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 LEU A 93 -52.03 -125.78 REMARK 500 SER A 173 -62.85 -92.91 REMARK 500 PHE A 216 -63.30 -126.41 REMARK 500 LYS A 287 -52.46 66.15 REMARK 500 LEU A 357 37.67 -70.40 REMARK 500 LEU B 93 -51.34 -126.12 REMARK 500 SER B 173 -68.51 -101.19 REMARK 500 PHE B 201 58.59 -92.64 REMARK 500 PHE B 216 -65.36 -126.64 REMARK 500 REMARK 500 REMARK: NULL REMARK 610 REMARK 610 MISSING HETEROATOM REMARK 610 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 610 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 610 I=INSERTION CODE): REMARK 610 M RES C SSEQI REMARK 610 2CV A 1360 REMARK 610 2CV B 1358 REMARK 610 2CV B 1359 REMARK 610 2CV B 1361 REMARK 610 2CV B 1362 REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE G90 A 1359 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 2CV A 1360 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 2CV B 1358 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 2CV B 1359 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC5 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE G90 B 1360 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC6 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 2CV B 1361 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC7 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 2CV B 1362 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1DEP RELATED DB: PDB REMARK 900 MEMBRANE PROTEIN, NMR, 1 STRUCTURE REMARK 900 RELATED ID: 2VT4 RELATED DB: PDB REMARK 900 TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND REMARK 900 BOUND CYANOPINDOLOL REMARK 900 RELATED ID: 2Y00 RELATED DB: PDB REMARK 900 TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND REMARK 900 BOUND PARTIAL AGONIST DOBUTAMINE (CRYSTAL DOB92) REMARK 900 RELATED ID: 2Y01 RELATED DB: PDB REMARK 900 TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND REMARK 900 BOUND PARTIAL AGONIST DOBUTAMINE (CRYSTAL DOB102) REMARK 900 RELATED ID: 2Y02 RELATED DB: PDB REMARK 900 TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND REMARK 900 BOUND AGONIST CARMOTEROL REMARK 900 RELATED ID: 2Y03 RELATED DB: PDB REMARK 900 TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND REMARK 900 BOUND AGONIST ISOPRENALINE REMARK 900 RELATED ID: 2Y04 RELATED DB: PDB REMARK 900 TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND REMARK 900 BOUND PARTIAL AGONIST SALBUTAMOL REMARK 900 RELATED ID: 2YCW RELATED DB: PDB REMARK 900 TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND REMARK 900 BOUND ANTAGONIST CARAZOLOL REMARK 900 RELATED ID: 2YCX RELATED DB: PDB REMARK 900 TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND REMARK 900 BOUND ANTAGONIST CYANOPINDOLOL REMARK 900 RELATED ID: 2YCY RELATED DB: PDB REMARK 900 TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND REMARK 900 BOUND ANTAGONIST CYANOPINDOLOL REMARK 900 RELATED ID: 2YCZ RELATED DB: PDB REMARK 900 TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND REMARK 900 BOUND ANTAGONIST IODOCYANOPINDOLOL REMARK 900 RELATED ID: 4AMJ RELATED DB: PDB REMARK 900 TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND REMARK 900 BOUND BIASED AGONIST CARVEDILOL REMARK 999 REMARK 999 SEQUENCE REMARK 999 THE FOLLOWING MUTATIONS WERE MADE TO IMPROVE REMARK 999 THERMOSTABILITY R68S,M90V,Y227A,A282L,F327A,F338M THE REMARK 999 FOLLOWING MUTATIONS WERE MADE TO IMPROVE EXPRESSION AND REMARK 999 HELP CRYSTALLISATION C116L, C358A DBREF 4AMI A 33 243 UNP P07700 ADRB1_MELGA 33 243 DBREF 4AMI A 272 368 UNP P07700 ADRB1_MELGA 272 368 DBREF 4AMI B 33 243 UNP P07700 ADRB1_MELGA 33 243 DBREF 4AMI B 272 368 UNP P07700 ADRB1_MELGA 272 368 SEQADV 4AMI MET A 31 UNP P07700 EXPRESSION TAG SEQADV 4AMI GLY A 32 UNP P07700 EXPRESSION TAG SEQADV 4AMI HIS A 369 UNP P07700 EXPRESSION TAG SEQADV 4AMI HIS A 370 UNP P07700 EXPRESSION TAG SEQADV 4AMI HIS A 371 UNP P07700 EXPRESSION TAG SEQADV 4AMI HIS A 372 UNP P07700 EXPRESSION TAG SEQADV 4AMI HIS A 373 UNP P07700 EXPRESSION TAG SEQADV 4AMI SER A 68 UNP P07700 ARG 68 ENGINEERED MUTATION SEQADV 4AMI VAL A 90 UNP P07700 MET 90 ENGINEERED MUTATION SEQADV 4AMI LEU A 116 UNP P07700 CYS 116 ENGINEERED MUTATION SEQADV 4AMI ALA A 227 UNP P07700 TYR 227 ENGINEERED MUTATION SEQADV 4AMI LEU A 282 UNP P07700 ALA 282 ENGINEERED MUTATION SEQADV 4AMI ALA A 327 UNP P07700 PHE 327 ENGINEERED MUTATION SEQADV 4AMI MET A 338 UNP P07700 PHE 338 ENGINEERED MUTATION SEQADV 4AMI ALA A 358 UNP P07700 CYS 358 ENGINEERED MUTATION SEQADV 4AMI MET B 31 UNP P07700 EXPRESSION TAG SEQADV 4AMI GLY B 32 UNP P07700 EXPRESSION TAG SEQADV 4AMI HIS B 369 UNP P07700 EXPRESSION TAG SEQADV 4AMI HIS B 370 UNP P07700 EXPRESSION TAG SEQADV 4AMI HIS B 371 UNP P07700 EXPRESSION TAG SEQADV 4AMI HIS B 372 UNP P07700 EXPRESSION TAG SEQADV 4AMI HIS B 373 UNP P07700 EXPRESSION TAG SEQADV 4AMI SER B 68 UNP P07700 ARG 68 ENGINEERED MUTATION SEQADV 4AMI VAL B 90 UNP P07700 MET 90 ENGINEERED MUTATION SEQADV 4AMI LEU B 116 UNP P07700 CYS 116 ENGINEERED MUTATION SEQADV 4AMI ALA B 227 UNP P07700 TYR 227 ENGINEERED MUTATION SEQADV 4AMI LEU B 282 UNP P07700 ALA 282 ENGINEERED MUTATION SEQADV 4AMI ALA B 327 UNP P07700 PHE 327 ENGINEERED MUTATION SEQADV 4AMI MET B 338 UNP P07700 PHE 338 ENGINEERED MUTATION SEQADV 4AMI ALA B 358 UNP P07700 CYS 358 ENGINEERED MUTATION SEQRES 1 A 315 MET GLY ALA GLU LEU LEU SER GLN GLN TRP GLU ALA GLY SEQRES 2 A 315 MET SER LEU LEU MET ALA LEU VAL VAL LEU LEU ILE VAL SEQRES 3 A 315 ALA GLY ASN VAL LEU VAL ILE ALA ALA ILE GLY SER THR SEQRES 4 A 315 GLN ARG LEU GLN THR LEU THR ASN LEU PHE ILE THR SER SEQRES 5 A 315 LEU ALA CYS ALA ASP LEU VAL VAL GLY LEU LEU VAL VAL SEQRES 6 A 315 PRO PHE GLY ALA THR LEU VAL VAL ARG GLY THR TRP LEU SEQRES 7 A 315 TRP GLY SER PHE LEU CYS GLU LEU TRP THR SER LEU ASP SEQRES 8 A 315 VAL LEU CYS VAL THR ALA SER ILE GLU THR LEU CYS VAL SEQRES 9 A 315 ILE ALA ILE ASP ARG TYR LEU ALA ILE THR SER PRO PHE SEQRES 10 A 315 ARG TYR GLN SER LEU MET THR ARG ALA ARG ALA LYS VAL SEQRES 11 A 315 ILE ILE CYS THR VAL TRP ALA ILE SER ALA LEU VAL SER SEQRES 12 A 315 PHE LEU PRO ILE MET MET HIS TRP TRP ARG ASP GLU ASP SEQRES 13 A 315 PRO GLN ALA LEU LYS CYS TYR GLN ASP PRO GLY CYS CYS SEQRES 14 A 315 ASP PHE VAL THR ASN ARG ALA TYR ALA ILE ALA SER SER SEQRES 15 A 315 ILE ILE SER PHE TYR ILE PRO LEU LEU ILE MET ILE PHE SEQRES 16 A 315 VAL ALA LEU ARG VAL TYR ARG GLU ALA LYS GLU GLN ILE SEQRES 17 A 315 ARG LYS ILE ASP ARG ALA SER LYS ARG LYS THR SER ARG SEQRES 18 A 315 VAL MET LEU MET ARG GLU HIS LYS ALA LEU LYS THR LEU SEQRES 19 A 315 GLY ILE ILE MET GLY VAL PHE THR LEU CYS TRP LEU PRO SEQRES 20 A 315 PHE PHE LEU VAL ASN ILE VAL ASN VAL PHE ASN ARG ASP SEQRES 21 A 315 LEU VAL PRO ASP TRP LEU PHE VAL ALA PHE ASN TRP LEU SEQRES 22 A 315 GLY TYR ALA ASN SER ALA MET ASN PRO ILE ILE TYR CYS SEQRES 23 A 315 ARG SER PRO ASP PHE ARG LYS ALA PHE LYS ARG LEU LEU SEQRES 24 A 315 ALA PHE PRO ARG LYS ALA ASP ARG ARG LEU HIS HIS HIS SEQRES 25 A 315 HIS HIS HIS SEQRES 1 B 315 MET GLY ALA GLU LEU LEU SER GLN GLN TRP GLU ALA GLY SEQRES 2 B 315 MET SER LEU LEU MET ALA LEU VAL VAL LEU LEU ILE VAL SEQRES 3 B 315 ALA GLY ASN VAL LEU VAL ILE ALA ALA ILE GLY SER THR SEQRES 4 B 315 GLN ARG LEU GLN THR LEU THR ASN LEU PHE ILE THR SER SEQRES 5 B 315 LEU ALA CYS ALA ASP LEU VAL VAL GLY LEU LEU VAL VAL SEQRES 6 B 315 PRO PHE GLY ALA THR LEU VAL VAL ARG GLY THR TRP LEU SEQRES 7 B 315 TRP GLY SER PHE LEU CYS GLU LEU TRP THR SER LEU ASP SEQRES 8 B 315 VAL LEU CYS VAL THR ALA SER ILE GLU THR LEU CYS VAL SEQRES 9 B 315 ILE ALA ILE ASP ARG TYR LEU ALA ILE THR SER PRO PHE SEQRES 10 B 315 ARG TYR GLN SER LEU MET THR ARG ALA ARG ALA LYS VAL SEQRES 11 B 315 ILE ILE CYS THR VAL TRP ALA ILE SER ALA LEU VAL SER SEQRES 12 B 315 PHE LEU PRO ILE MET MET HIS TRP TRP ARG ASP GLU ASP SEQRES 13 B 315 PRO GLN ALA LEU LYS CYS TYR GLN ASP PRO GLY CYS CYS SEQRES 14 B 315 ASP PHE VAL THR ASN ARG ALA TYR ALA ILE ALA SER SER SEQRES 15 B 315 ILE ILE SER PHE TYR ILE PRO LEU LEU ILE MET ILE PHE SEQRES 16 B 315 VAL ALA LEU ARG VAL TYR ARG GLU ALA LYS GLU GLN ILE SEQRES 17 B 315 ARG LYS ILE ASP ARG ALA SER LYS ARG LYS THR SER ARG SEQRES 18 B 315 VAL MET LEU MET ARG GLU HIS LYS ALA LEU LYS THR LEU SEQRES 19 B 315 GLY ILE ILE MET GLY VAL PHE THR LEU CYS TRP LEU PRO SEQRES 20 B 315 PHE PHE LEU VAL ASN ILE VAL ASN VAL PHE ASN ARG ASP SEQRES 21 B 315 LEU VAL PRO ASP TRP LEU PHE VAL ALA PHE ASN TRP LEU SEQRES 22 B 315 GLY TYR ALA ASN SER ALA MET ASN PRO ILE ILE TYR CYS SEQRES 23 B 315 ARG SER PRO ASP PHE ARG LYS ALA PHE LYS ARG LEU LEU SEQRES 24 B 315 ALA PHE PRO ARG LYS ALA ASP ARG ARG LEU HIS HIS HIS SEQRES 25 B 315 HIS HIS HIS HET G90 A1359 27 HET 2CV A1360 17 HET 2CV B1358 15 HET 2CV B1359 14 HET G90 B1360 27 HET 2CV B1361 23 HET 2CV B1362 8 HETNAM G90 2-[(2S)-3-[[1-(1H-INDOL-3-YL)-2-METHYL-PROPAN-2- HETNAM 2 G90 YL]AMINO]-2-OXIDANYL-PROPOXY]BENZENECARBONITRILE HETNAM 2CV HEGA-10 HETSYN G90 BUCINDOLOL FORMUL 3 G90 2(C22 H25 N3 O2) FORMUL 4 2CV 5(C18 H37 N O7) FORMUL 10 HOH *13(H2 O) HELIX 1 1 ALA A 33 THR A 69 1 37 HELIX 2 2 LEU A 75 LEU A 93 1 19 HELIX 3 3 LEU A 93 GLY A 105 1 13 HELIX 4 4 TRP A 109 SER A 145 1 37 HELIX 5 5 SER A 145 MET A 153 1 9 HELIX 6 6 THR A 154 MET A 179 1 26 HELIX 7 7 ASP A 186 ASP A 195 1 10 HELIX 8 8 ASN A 204 PHE A 216 1 13 HELIX 9 9 PHE A 216 GLN A 237 1 22 HELIX 10 10 LYS A 287 ASN A 316 1 30 HELIX 11 11 PRO A 321 ASN A 335 1 15 HELIX 12 12 ALA A 337 TYR A 343 1 7 HELIX 13 13 SER A 346 LEU A 357 1 12 HELIX 14 14 ALA B 33 THR B 69 1 37 HELIX 15 15 LEU B 75 LEU B 93 1 19 HELIX 16 16 LEU B 93 GLY B 105 1 13 HELIX 17 17 TRP B 109 SER B 145 1 37 HELIX 18 18 SER B 145 MET B 153 1 9 HELIX 19 19 THR B 154 MET B 179 1 26 HELIX 20 20 ASP B 186 ASP B 195 1 10 HELIX 21 21 ASN B 204 PHE B 216 1 13 HELIX 22 22 PHE B 216 ARG B 239 1 24 HELIX 23 23 SER B 278 ASN B 316 1 39 HELIX 24 24 PRO B 321 ASN B 335 1 15 HELIX 25 25 ALA B 337 TYR B 343 1 7 HELIX 26 26 SER B 346 LEU B 357 1 12 SSBOND 1 CYS A 114 CYS A 199 1555 1555 2.04 SSBOND 2 CYS A 192 CYS A 198 1555 1555 2.04 SSBOND 3 CYS B 114 CYS B 199 1555 1555 2.04 SSBOND 4 CYS B 192 CYS B 198 1555 1555 2.04 SITE 1 AC1 12 TRP A 117 ASP A 121 VAL A 122 VAL A 125 SITE 2 AC1 12 CYS A 199 PHE A 201 SER A 211 SER A 215 SITE 3 AC1 12 TRP A 303 PHE A 306 ASN A 310 ASN A 329 SITE 1 AC2 4 ARG A 183 ASN A 204 TYR A 207 THR B 164 SITE 1 AC3 1 ILE B 214 SITE 1 AC4 3 ARG A 157 ARG B 205 2CV B1361 SITE 1 AC5 11 TRP B 117 ASP B 121 VAL B 122 VAL B 125 SITE 2 AC5 11 CYS B 199 ASP B 200 SER B 211 SER B 215 SITE 3 AC5 11 TRP B 303 PHE B 306 ASN B 329 SITE 1 AC6 6 VAL A 160 THR A 164 ARG B 183 ASP B 184 SITE 2 AC6 6 GLU B 185 2CV B1359 SITE 1 AC7 1 ILE B 161 CRYST1 89.844 60.677 107.818 90.00 110.78 90.00 P 1 21 1 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.011130 0.000000 0.004224 0.00000 SCALE2 0.000000 0.016481 0.000000 0.00000 SCALE3 0.000000 0.000000 0.009920 0.00000 MTRIX1 1 1.000000 0.000000 0.000000 0.00000 1 MTRIX2 1 0.000000 1.000000 0.000000 0.00000 1 MTRIX3 1 0.000000 0.000000 1.000000 0.00000 1 MTRIX1 2 -0.999443 0.033183 0.003584 -15.10151 1 MTRIX2 2 0.029228 0.818309 0.574035 -15.01030 1 MTRIX3 2 0.016115 0.573820 -0.818823 48.81022 1